Savvy Advisors Inc. Makes New $202,000 Investment in Edwards Lifesciences Corporation $EW

Savvy Advisors Inc. bought a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 2,587 shares of the medical research company’s stock, valued at approximately $202,000.

Other institutional investors also recently made changes to their positions in the company. Econ Financial Services Corp acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at about $889,000. Allspring Global Investments Holdings LLC grew its position in Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after buying an additional 145 shares during the period. Pacific Capital Partners Ltd purchased a new position in Edwards Lifesciences in the second quarter valued at about $1,760,000. Czech National Bank lifted its position in shares of Edwards Lifesciences by 5.8% during the 2nd quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock valued at $11,214,000 after acquiring an additional 7,917 shares during the period. Finally, Mirova US LLC boosted its stake in shares of Edwards Lifesciences by 56.2% during the 2nd quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock worth $229,257,000 after acquiring an additional 1,054,301 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Down 1.2%

EW opened at $82.48 on Monday. The firm has a market cap of $48.42 billion, a P/E ratio of 11.87, a PEG ratio of 3.97 and a beta of 1.05. The business’s fifty day simple moving average is $77.58 and its 200 day simple moving average is $76.97. Edwards Lifesciences Corporation has a 52 week low of $64.89 and a 52 week high of $87.09. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the firm earned $0.67 EPS. The firm’s quarterly revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Stifel Nicolaus raised their price objective on Edwards Lifesciences from $85.00 to $95.00 and gave the company a “buy” rating in a research note on Friday. Mizuho raised their price target on Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Friday. Morgan Stanley boosted their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th. BTIG Research raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a research note on Tuesday, July 29th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $91.00.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.